Literature DB >> 33470406

In search of predictive and response markers in antiangiogenic therapy of glioblastoma.

Adam A Dmytriw1, Raymond Y Huang1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33470406      PMCID： PMC7906059          DOI： 10.1093/neuonc/noaa293

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  9 in total

1.  Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma.

Authors:  Elizabeth R Gerstner; Kyrre E Emblem; Ken Chang; Bella Vakulenko-Lagun; Yi-Fen Yen; Andrew L Beers; Jorg Dietrich; Scott R Plotkin; Ciprian Catana; Jacob M Hooker; Dan G Duda; Bruce Rosen; Jayashree Kalpathy-Cramer; Rakesh K Jain; Tracy Batchelor
Journal:  Clin Cancer Res       Date:  2019-09-26       Impact factor: 12.531

2.  Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.

Authors:  Philipp Kickingereder; Gianluca Brugnara; Mikkel Bo Hansen; Martha Nowosielski; Irada Pflüger; Marianne Schell; Fabian Isensee; Martha Foltyn; Ulf Neuberger; Tobias Kessler; Felix Sahm; Antje Wick; Sabine Heiland; Michael Weller; Michael Platten; Andreas von Deimling; Klaus H Maier-Hein; Leif Østergaard; Martin J van den Bent; Thierry Gorlia; Wolfgang Wick; Martin Bendszus
Journal:  Radiology       Date:  2020-07-28       Impact factor: 11.105

Review 3.  Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.

Authors:  Rakesh K Jain
Journal:  Cancer Cell       Date:  2014-11-10       Impact factor: 31.743

4.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Authors:  Olivier L Chinot; Wolfgang Wick; Warren Mason; Roger Henriksson; Frank Saran; Ryo Nishikawa; Antoine F Carpentier; Khe Hoang-Xuan; Petr Kavan; Dana Cernea; Alba A Brandes; Magalie Hilton; Lauren Abrey; Timothy Cloughesy
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

5.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

6.  Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.

Authors:  Philipp Kickingereder; Benedikt Wiestler; Sina Burth; Antje Wick; Martha Nowosielski; Sabine Heiland; Heinz-Peter Schlemmer; Wolfgang Wick; Martin Bendszus; Alexander Radbruch
Journal:  Neuro Oncol       Date:  2015-03-09       Impact factor: 12.300

7.  Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas.

Authors:  Jerrold L Boxerman; Chad C Quarles; Leland S Hu; Bradley J Erickson; Elizabeth R Gerstner; Marion Smits; Timothy J Kaufmann; Daniel P Barboriak; Raymond H Huang; Wolfgang Wick; Michael Weller; Evanthia Galanis; Jayashree Kalpathy-Cramer; Lalitha Shankar; Paula Jacobs; Caroline Chung; Martin J van den Bent; Susan Chang; W K Al Yung; Timothy F Cloughesy; Patrick Y Wen; Mark R Gilbert; Bruce R Rosen; Benjamin M Ellingson; Kathleen M Schmainda
Journal:  Neuro Oncol       Date:  2020-09-29       Impact factor: 12.300

Review 8.  Perfusion MRI in treatment evaluation of glioblastomas: Clinical relevance of current and future techniques.

Authors:  Bart R J van Dijken; Peter Jan van Laar; Marion Smits; Jan Willem Dankbaar; Roelien H Enting; Anouk van der Hoorn
Journal:  J Magn Reson Imaging       Date:  2019-01       Impact factor: 4.813

9.  Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial.

Authors:  Kathleen M Schmainda; Melissa A Prah; Helga Marques; Eunhee Kim; Daniel P Barboriak; Jerrold L Boxerman
Journal:  Neuro Oncol       Date:  2021-02-25       Impact factor: 13.029
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.